SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Karim Fifel, Hugh Piggins, Tom Deboer, Modeling sleep alterations in Parkinson's disease: How close are we to valid translational animal models?, Sleep Medicine Reviews, 2016, 25, 95

    CrossRef

  2. 2
    Mechelle M. Lewis, Guangwei Du, Eun-Young Lee, Zeinab Nasralah, Nicholas W. Sterling, Lijun Zhang, Daymond Wagner, Lan Kong, Alexander I. Tröster, Martin Styner, Paul J. Eslinger, Richard B. Mailman, Xuemei Huang, The pattern of gray matter atrophy in Parkinson’s disease differs in cortical and subcortical regions, Journal of Neurology, 2016, 263, 1, 68

    CrossRef

  3. 3
    Ji-feng Kang, Bei-sha Tang, Ji-feng Guo, The Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease, Stem Cells International, 2016, 2016, 1

    CrossRef

  4. 4
    Yue Yang, Claire Shepherd, Glenda Halliday, Aneuploidy in Lewy body diseases, Neurobiology of Aging, 2015, 36, 3, 1253

    CrossRef

  5. 5
    Inga Liepelt-Scarfone, Andrea Pilotto, Katharina Müller, Christian Bormann, Katharina Gauss, Isabel Wurster, Johannes Streffer, Daniela Berg, Autonomic dysfunction in subjects at high risk for Parkinson’s disease, Journal of Neurology, 2015, 262, 12, 2643

    CrossRef

  6. 6
    Angelo Del Sole, Giulia Perini, Michela Lecchi, Claudio Mariani, Giovanni Lucignani, Francesca Clerici, Correlation Between 123I-FP-CIT Brain SPECT and Parkinsonism in Dementia With Lewy Bodies, Clinical Nuclear Medicine, 2015, 40, 1, 32

    CrossRef

  7. 7
    Ledia F. Hernández, Peter Redgrave, José A. Obeso, Habitual behavior and dopamine cell vulnerability in Parkinson disease, Frontiers in Neuroanatomy, 2015, 9,

    CrossRef

  8. 8
    D. H. Lee, J. S. Oh, J. H. Ham, J. J. Lee, I. Lee, P. H. Lee, J. S. Kim, Y. H. Sohn, Is normosmic Parkinson disease a unique clinical phenotype?, Neurology, 2015, 85, 15, 1270

    CrossRef

  9. 9
    Kazuki Ide, Hiroshi Yamada, Keizo Umegaki, Katsuki Mizuno, Nobuko Kawakami, Yuka Hagiwara, Mizuki Matsumoto, Hidefumi Yoshida, Kang Kim, Emi Shiosaki, Tsunehiro Yokochi, Kiyoshi Harada, Lymphocyte vitamin C levels as potential biomarker for progression of Parkinson's disease, Nutrition, 2015, 31, 2, 406

    CrossRef

  10. 10
    Andrew L. Eagle, Oluyemi O. Olumolade, Hajime Otani, Partial dopaminergic denervation-induced impairment in stimulus discrimination acquisition in parkinsonian rats: A model for early Parkinson's disease, Neuroscience Research, 2015, 92, 71

    CrossRef

  11. 11
    Kobra Zare, Akram Eidi, Mehrdad Roghani, Ali Haeri Rohani, The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat, Metabolic Brain Disease, 2015, 30, 1, 205

    CrossRef

  12. 12
    Manuel Multhammer, Andreas Michels, Maria Zintl, Maria Cristina Mendoza, Hans-Hermann Klünemann, A large ApoE ε4/ε4 homozygous cohort reveals no association with Parkinson’s disease, Acta Neurologica Belgica, 2014, 114, 1, 25

    CrossRef

  13. 13
    Sarah K. Abbott, Hongyun Li, Sonia Sanz Muñoz, Bianca Knoch, Marijka Batterham, Karen E. Murphy, Glenda M. Halliday, Brett Garner, Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease, Movement Disorders, 2014, 29, 4
  14. 14
    Monika Białecka, Mateusz Kurzawski, Anna Roszmann, Piotr Robowski, Emilia J. Sitek, Krystyna Honczarenko, Monika Mak, Monika Deptuła-Jarosz, Monika Gołąb-Janowska, Marek Droździk, Jarosław Sławek, BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease, Neuroscience Letters, 2014, 561, 86

    CrossRef

  15. 15
    Emilia Michou, Shaheen Hamdy, Mary Harris, Adil Vania, Jeremy Dick, Mark Kellett, John Rothwell, Characterization of Corticobulbar Pharyngeal Neurophysiology in Dysphagic Patients With Parkinson's Disease, Clinical Gastroenterology and Hepatology, 2014, 12, 12, 2037

    CrossRef

  16. 16
    David Burn, Daniel Weintraub, Bernard Ravina, Irene Litvan, Cognition in movement disorders: Where can we hope to be in ten years?, Movement Disorders, 2014, 29, 5
  17. 17
    Lisa Klingelhoefer, Heinz Reichmann, Dementia – The real problem for patients with Parkinson's disease, Basal Ganglia, 2014, 4, 1, 9

    CrossRef

  18. 18
    Iakov N. Rudenko, Mark R. Cookson, Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms and Therapeutic Implications, Neurotherapeutics, 2014, 11, 4, 738

    CrossRef

  19. 19
    Shu-yang Yu, Li-jun Zuo, Fang Wang, Ze-jie Chen, Yang Hu, Ya-jie Wang, Xiao-min Wang, Wei Zhang, Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study, BMC Neurology, 2014, 14, 1, 113

    CrossRef

  20. 20
    K. E. Murphy, A. M. Gysbers, S. K. Abbott, N. Tayebi, W. S. Kim, E. Sidransky, A. Cooper, B. Garner, G. M. Halliday, Reduced glucocerebrosidase is associated with increased  -synuclein in sporadic Parkinson's disease, Brain, 2014, 137, 3, 834

    CrossRef

  21. 21
    Anke A. Dijkstra, Pieter Voorn, Henk W. Berendse, Henk J. Groenewegen, Annemieke J.M. Rozemuller, Wilma D.J. Berg, Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease, Movement Disorders, 2014, 29, 10
  22. 22
    Glenda M. Halliday, James B. Leverenz, Jay S. Schneider, Charles H. Adler, The neurobiological basis of cognitive impairment in Parkinson's disease, Movement Disorders, 2014, 29, 5
  23. 23
    Heather McCann, Claire H. Stevens, Heidi Cartwright, Glenda M. Halliday, α-Synucleinopathy phenotypes, Parkinsonism & Related Disorders, 2014, 20, S62

    CrossRef

  24. 24
    Gordon W. Arbuthnott, Dopamine, 2014,

    CrossRef

  25. 25
    M.M. Ponsen, C.J. Stam, J.L.W. Bosboom, H.W. Berendse, A. Hillebrand, A three dimensional anatomical view of oscillatory resting-state activity and functional connectivity in Parkinson's disease related dementia: An MEG study using atlas-based beamforming, NeuroImage: Clinical, 2013, 2, 95

    CrossRef

  26. 26
    Rosanna Squitti, Renato Polimanti, Mariacristina Siotto, Serena Bucossi, Mariacarla Ventriglia, Stefania Mariani, Fabrizio Vernieri, Federica Scrascia, Laura Trotta, Paolo Maria Rossini, ATP7B Variants as Modulators of Copper Dyshomeostasis in Alzheimer’s Disease, NeuroMolecular Medicine, 2013, 15, 3, 515

    CrossRef

  27. 27
    André C. Marreiros, Hayriye Cagnan, Rosalyn J. Moran, Karl J. Friston, Peter Brown, Basal ganglia–cortical interactions in Parkinsonian patients, NeuroImage, 2013, 66, 301

    CrossRef

  28. 28
    Mona K. Beyer, Guido Alves, Kristy S. Hwang, Sona Babakchanian, Kolbjorn S. Bronnick, Yi-Yu Chou, Turi O. Dalaker, Martin W. Kurz, Jan P. Larsen, Johanne H. Somme, Paul M. Thompson, Ole-Bjørn Tysnes, Liana G. Apostolova, Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease, Movement Disorders, 2013, 28, 3
  29. 29
    Jennifer Weuve, Daniel Z. Press, Francine Grodstein, Robert O. Wright, Howard Hu, Marc G. Weisskopf, Cumulative exposure to lead and cognition in persons with Parkinson's disease, Movement Disorders, 2013, 28, 2
  30. 30
    Federica Agosta, Francesca Caso, Massimo Filippi, Dementia and neuroimaging, Journal of Neurology, 2013, 260, 2, 685

    CrossRef

  31. 31
    R. P. Munhoz, H. A. Teive, H. Eleftherohorinou, L. J. Coin, A. J. Lees, L. Silveira-Moriyama, Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease, Journal of Neurology, Neurosurgery & Psychiatry, 2013, 84, 8, 883

    CrossRef

  32. 32
    Nicolas Daviaud, Elisa Garbayo, Paul C. Schiller, Miguel Perez-Pinzon, Claudia N. Montero-Menei, Organotypic cultures as tools for optimizing central nervous system cell therapies, Experimental Neurology, 2013, 248, 429

    CrossRef

  33. 33
    Rita Perfeito, Teresa Cunha-Oliveira, Ana Cristina Rego, Reprint of: Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease—resemblance to the effect of amphetamine drugs of abuse, Free Radical Biology and Medicine, 2013, 62, 186

    CrossRef

  34. 34
    Kathy Dujardin, Albert F.G. Leentjens, Carole Langlois, Anja J.H. Moonen, Annelien A. Duits, Anne-Sophie Carette, Alain Duhamel, The spectrum of cognitive disorders in Parkinson's disease: A data-driven approach, Movement Disorders, 2013, 28, 2
  35. 35
    Kelvin C. Luk, Vladimir V. Rymar, Pepijn den Munckhof, Stefan Nicolau, Claude Steriade, Panojot Bifsha, Jacques Drouin, Abbas F. Sadikot, The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress, Journal of Neurochemistry, 2013, 125, 6
  36. 36
    Arianna Bellucci, Laura Navarria, Michela Zaltieri, Cristina Missale, PierFranco Spano, Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease, Brain Research, 2012, 1432, 95

    CrossRef

  37. 37
    Monika Białecka, Mateusz Kurzawski, Anna Roszmann, Piotr Robowski, Emilia J. Sitek, Krystyna Honczarenko, Agnieszka Gorzkowska, Sławomir Budrewicz, Monika Mak, Monika Jarosz, Monika Gołąb-Janowska, Ewa Koziorowska-Gawron, Marek Droździk, Jarosław Sławek, Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson’s disease, Pharmacogenetics and Genomics, 2012, 22, 10, 716

    CrossRef

  38. 38
    Christopher J.R. Dunning, Juan F. Reyes, Jennifer A. Steiner, Patrik Brundin, Can Parkinson's disease pathology be propagated from one neuron to another?, Progress in Neurobiology, 2012, 97, 2, 205

    CrossRef

  39. 39
    Per Svenningsson, Eric Westman, Clive Ballard, Dag Aarsland, Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment, The Lancet Neurology, 2012, 11, 8, 697

    CrossRef

  40. 40
    Daniela Berg, Ken Marek, George W. Ross, Werner Poewe, Defining at-risk populations for Parkinson's disease: Lessons from ongoing studies, Movement Disorders, 2012, 27, 5
  41. 41
    Glenda Halliday, Heather McCann, Claire Shepherd, Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?, Expert Review of Neurotherapeutics, 2012, 12, 6, 673

    CrossRef

  42. 42
    Arianna Bellucci, Michela Zaltieri, Laura Navarria, Jessica Grigoletto, Cristina Missale, PierFranco Spano, From α-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease, Brain Research, 2012, 1476, 183

    CrossRef

  43. 43
    Ronald B. Postuma, Dag Aarsland, Paolo Barone, David J. Burn, Christopher H. Hawkes, Wolfgang Oertel, Tjalf Ziemssen, Identifying prodromal Parkinson's disease: Pre-Motor disorders in Parkinson's disease, Movement Disorders, 2012, 27, 5
  44. 44
    Heather B Patisaul, Sandra M Losa-Ward, Karina L Todd, Katherine A McCaffrey, Jillian A Mickens, Influence of ERβ selective agonism during the neonatal period on the sexual differentiation of the rat hypothalamic-pituitary-gonadal (HPG) axis, Biology of Sex Differences, 2012, 3, 1, 2

    CrossRef

  45. 45
    Dominic Nadeau, Isabelle Giroux, Julie Dufour, Martine Simard, Jeu pathologique chez les patients atteints de la maladie de Parkinson, Santé mentale au Québec, 2012, 37, 1, 189

    CrossRef

  46. 46
    Naima Maouche, Mounia Guergouri, Sarra Gam-Derouich, Mohamed Jouini, Belkacem Nessark, Mohamed M. Chehimi, Molecularly imprinted polypyrrole films: Some key parameters for electrochemical picomolar detection of dopamine, Journal of Electroanalytical Chemistry, 2012, 685, 21

    CrossRef

  47. You have free access to this content47
    Abdul Qayyum Rana, Muhammad Saad Yousuf, Sughra Naz, Nour Qa'aty, Prevalence and relation of dementia to various factors in Parkinson's disease, Psychiatry and Clinical Neurosciences, 2012, 66, 1
  48. 48
    Rita Perfeito, Teresa Cunha-Oliveira, Ana Cristina Rego, Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease—resemblance to the effect of amphetamine drugs of abuse, Free Radical Biology and Medicine, 2012, 53, 9, 1791

    CrossRef

  49. 49
    Valerie Z. Wall, Jones G. Parker, Jonathan P. Fadok, Martin Darvas, Larry Zweifel, Richard D. Palmiter, A behavioral genetics approach to understanding D1 receptor involvement in phasic dopamine signaling, Molecular and Cellular Neuroscience, 2011, 46, 1, 21

    CrossRef

  50. 50
    Toru Baba, Atsushi Takeda, Akio Kikuchi, Yoshiyuki Nishio, Yoshiyuki Hosokai, Kazumi Hirayama, Takafumi Hasegawa, Naoto Sugeno, Kyoko Suzuki, Etsuro Mori, Shoki Takahashi, Hiroshi Fukuda, Yasuto Itoyama, Association of olfactory dysfunction and brain. Metabolism in Parkinson's disease, Movement Disorders, 2011, 26, 4
  51. 51
    Viola Oertel-Knöchel, Robert A. Bittner, Christian Knöchel, David Prvulovic, Harald Hampel, Discovery and development of integrative biological markers for schizophrenia, Progress in Neurobiology, 2011, 95, 4, 686

    CrossRef

  52. 52
    ÁGNES FEHÉR, ANNA JUHÁSZ, ÁGNES RIMANÓCZY, PÉTER ÁLMOS, JUDIT BÉRES, ZOLTÁN JANKA, JÁNOS KÁLMÁN, Dopamine metabolism-related gene polymorphisms in Roma (Gypsy) and Hungarian populations, Journal of Genetics, 2011,

    CrossRef

  53. 53
    Elisabetta Gianazza, Ivano Eberini, Cristina Sensi, Maria Barile, Lodovica Vergani, Maria Antonietta Vanoni, Energy matters: Mitochondrial proteomics for biomedicine, PROTEOMICS, 2011, 11, 4
  54. 54
    C. Di Caudo, M.R. Luquin, Enfermedad de Parkinson, Medicine - Programa de Formación Médica Continuada Acreditado, 2011, 10, 73, 4944

    CrossRef

  55. 55
    Glenda Halliday, Andrew Lees, Matthew Stern, Milestones in Parkinson's disease—Clinical and pathologic features, Movement Disorders, 2011, 26, 6
  56. 56
    Glenda M. Halliday, Janice L. Holton, Tamas Revesz, Dennis W. Dickson, Neuropathology underlying clinical variability in patients with synucleinopathies, Acta Neuropathologica, 2011, 122, 2, 187

    CrossRef

  57. 57
    Maria Trinidad Herrero, Javier Pagonabarraga, Gurutz Linazasoro, Neuroprotective Role of Dopamine Agonists, The Neurologist, 2011, 17, S54

    CrossRef

  58. You have free access to this content58
    John N. Caviness, LihFen Lue, Charles H. Adler, Douglas G. Walker, Parkinson's Disease Dementia and Potential Therapeutic Strategies, CNS Neuroscience & Therapeutics, 2011, 17, 1
  59. 59
    C. Gibrat, F. Cicchetti, Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 2, 380

    CrossRef

  60. 60
    Kurt A. Jellinger, Johannes Attems, Prevalence and Pathology of Dementia with Lewy Bodies in the Oldest Old: A Comparison with Other Dementing Disorders, Dementia and Geriatric Cognitive Disorders, 2011, 31, 4, 309

    CrossRef

  61. 61
    R. L. Boudreau, E. Rodriguez-Lebron, B. L. Davidson, RNAi medicine for the brain: progresses and challenges, Human Molecular Genetics, 2011, 20, R1, R21

    CrossRef

  62. 62
    Sayaka Asari, Ken-ichi Fujimoto, Akihiro Miyauchi, Toshihiko Sato, Imaharu Nakano, Shin-ichi Muramatsu, Subregional 6-[18F]fluoro-ʟ-m-tyrosine Uptake in the Striatum in Parkinson's Disease, BMC Neurology, 2011, 11, 1, 35

    CrossRef

  63. 63
    Chia-Wei Hung, Yu-Chih Chen, Wan-Ling Hsieh, Shih-Hwa Chiou, Chung-Lan Kao, Ageing and neurodegenerative diseases, Ageing Research Reviews, 2010, 9, S36

    CrossRef

  64. 64
    Elodie Angot, Jennifer A Steiner, Christian Hansen, Jia-Yi Li, Patrik Brundin, Are synucleinopathies prion-like disorders?, The Lancet Neurology, 2010, 9, 11, 1128

    CrossRef

  65. 65
    Zhihao Zou, Xiaodan Jiang, Wangming Zhang, Yuan Zhou, Yiquan Ke, Shizhong Zhang, Ruxiang Xu, Efficacy of Tyrosine Hydroxylase gene modified neural stem cells derived from bone marrow on Parkinson's disease – a rat model study, Brain Research, 2010, 1346, 279

    CrossRef

  66. 66
    Jakob Nyhlén, Radu Constantinescu, Henrik Zetterberg, Problems associated with fluid biomarkers for Parkinson’s disease, Biomarkers in Medicine, 2010, 4, 5, 671

    CrossRef

  67. 67
    Mark R. Cookson, The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease, Nature Reviews Neuroscience, 2010, 11, 12, 791

    CrossRef

  68. 68
    Volodymyr V. Shvadchak, Lisandro J. Falomir-Lockhart, Dmytro A. Yushchenko, Thomas M. Jovin, Interactions of α-Synuclein with Lipids and Artificial Membranes Monitored by ESIPT Probes,